T.G. SAKOVETS

Kazan State Medical University, 49 Butlerov St., Kazan, Russian Federation, 420012

Sakovets T.G. — Cand. Med. Sc., Assistant of the Department of Neurology and Rehabilitation, tel. +7-909-307-94-77, e-mail: tsakovets@yandex.ru

Painful neuropathy caused by genetic, infectious factors, metabolic, endocrinological disorders, infectious diseases, systemic connective tissue diseases, vitamin deficiencies, inflammatory, paraneoplastic processes, impact heavy metals, alcohol, drugs. Neuropathic pain is often dominant syndrome with painful neuropathies. Typical manifestations of neuropathic pain are considered positive sensory phenomena, burning, sharp, shooting, and/or deep bursting pain, hyperalgesia, allodynia, dysesthesia, paresthesia), negative clinical symptoms presented by the disturbance surface sensitivity. Neuropathic pain often lead to disability and long-term disability of the patient with professional, social and psychological maladjustment, determining the importance of adequate selection of medicines. The most effective in the treatment of neuropathic pain are considered as anticonvulsants, antidepressants, are also used opiate analgesics, neurotrophic factors. In experimental medicine actively explores new drug substances and substances that may be effective in treating neuropathic pain.

Key words: neuropathic pain, painful neuropathy, neuropathic pain therapy.

REFERENCES

1. Sada H., Egashira N., Ushio S. et al. Repeated administration of amitriptyline reduces oxaliplatin-induced mechanical allodynia in rats. J. Pharmacol. Sci, 2012, vol. 118, no. 4, pp. 547-551.
2. Hughes L.M., Wiffen R.A. Philip Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. J. Cochrane Database Syst. Rev, 2014-01-02.
3. Finnerup B.N., Sindrup H.S., Staehelin J.T. Management of painful neuropathies. Handb. Clin. Neurol, 2013, vol. 115, pp. 279-290.
4. Meregalli C., Ceresa C., Canta A. et al. CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats. J. Pain Res, 2012, vol. 5, rr. 151-167.
5. Masuguchi K., Watanabe H., Kawashiri T. et al. Neurotropin® relieves oxaliplatin-induced neuropathy via Gi protein-coupled receptors in the monoaminergic descending pain inhibitory system. Life Sci, 2014, vol. 98, no. 1, pp. 49-54.
6. Schreiber A.K., Neufeld M., Jesus C.H. Peripheral antinociceptive effect of anandamide and drugs that affect the endocannabinoid system on the formalin test in normal and streptozotocin-diabetic rats. Neuropharmacology, 2012, vol. 63, no. 8, pp. 1286-1297.
7. Isose S., Misawa S., Sawai S. Mexiletine suppresses excessive axonal persistent sodium currents in painful neuropathy. Clinical Neurophysiology, 2008, vol. 119, no. 6, pp. 92-92.
8. Truini A., Biasiotta A., Di Stefano G. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol. Disord. Drug Targets, 2011, vol. 10, no. 8, pp. 916-920.
9. Bogdanov E.I., Sakovets T.G. Features of the etiology, pathogenesis and clinical manifestations of painful neuropathy. Nevrologicheskiy vestnik, 2014, no. 3, pp. 28-34 (in Russ.).